141 related articles for article (PubMed ID: 26702369)
1. Effective recovery of highly purified CD326(+) tumor cells from lavage fluid of patients treated with a novel cell-free and concentrated ascites reinfusion therapy (KM-CART).
Kimura Y; Harada Y; Yasuda N; Ishidao T; Yusa S; Matsusaki K; Yonemitsu Y
Springerplus; 2015; 4():780. PubMed ID: 26702369
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of Patients and Their Ascites Who Underwent Repeated Cell-Free and Concentrated Ascites Reinfusion Therapy.
Maeda S; Yabuuchi J; Nobuta H; Makiishi T; Hirose K
Ther Apher Dial; 2015 Aug; 19(4):342-8. PubMed ID: 26386222
[TBL] [Abstract][Full Text] [Related]
3. Immunological Analysis and Generation of Dendritic Cells From Lavage Fluid Obtained by Cell-Free and Concentrated Ascites Reinfusion Therapy.
Ogasawara M; Miyashita M; Iida M; Fukuhara T
Ther Apher Dial; 2017 Jun; 21(3):255-262. PubMed ID: 28661089
[TBL] [Abstract][Full Text] [Related]
4. Safety of repeated cell-free and concentrated ascites reinfusion therapy for malignant ascites from gastrointestinal cancer.
Maeda O; Ando T; Ishiguro K; Watanabe O; Miyahara R; Nakamura M; Funasaka K; Kazuhiro F; Ando Y; Goto H
Mol Clin Oncol; 2014 Nov; 2(6):1103-1106. PubMed ID: 25279205
[TBL] [Abstract][Full Text] [Related]
5. Technical Performance and Clinical Effectiveness of Drop Type With Adjustable Concentrator-Cell Free and Concentrated Ascites Reinfusion Therapy.
Yamada Y; Harada M; Yamaguchi A; Kobayashi Y; Chino T; Minowa T; Kosuge T; Tsukada W; Hashimoto K; Kamijo Y
Artif Organs; 2017 Dec; 41(12):1135-1144. PubMed ID: 28589706
[TBL] [Abstract][Full Text] [Related]
6. Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1.
Yamaguchi H; Kitayama J; Emoto S; Ishigami H; Ito T; Hanafusa N; Watanabe T
Eur J Surg Oncol; 2015 Jul; 41(7):875-80. PubMed ID: 25986856
[TBL] [Abstract][Full Text] [Related]
7. Adverse effects of cell-free and concentrated ascites reinfusion therapy for malignant ascites: a single-institute experience.
Tsubokura M; Adegawa Y; Kojima M; Tanosaki R; Ohtake R; Kase Y; Iwashita N; Kasane M; Nakabayashi S; Takeuchi S; Kato K; Boku N; Kanemitsu Y; Okusaka T; Fujimoto H; Yonemori K; Ishiki H; Kawamura K; Satomi E; Matsushita H
BMC Cancer; 2022 Mar; 22(1):268. PubMed ID: 35287609
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results.
Hanafusa N; Isoai A; Ishihara T; Inoue T; Ishitani K; Utsugisawa T; Yamaka T; Ito T; Sugiyama H; Arakawa A; Yamada Y; Itano Y; Onodera H; Kobayashi R; Torii N; Numata T; Kashiwabara T; Matsuno Y; Kato M
PLoS One; 2017; 12(5):e0177303. PubMed ID: 28510606
[TBL] [Abstract][Full Text] [Related]
9. Development of a novel automatic ascites filtration and concentration equipment with multi-ring-type roller pump units for cell-free and concentrated ascites reinfusion therapy.
Okahisa T; Sogabe M; Nakagawa T; Tanaka K; Tomonari T; Taniguchi T; Takahashi A; Kinouchi Y; Nishioka J; Igata N; Yanagawa H; Komatsu T; Ohnishi Y; Fukuhara M; Ishikawa M; Shibata H; Shinomiya H; Nakasono M; Kishi F; Komai K; Tatsuki Y; Murashima T; Deguchi Y; Aramaki H; Fukumitsu H; Takayama T
Artif Organs; 2020 Aug; 44(8):856-872. PubMed ID: 32187379
[TBL] [Abstract][Full Text] [Related]
10. A Method for Stabilizing the Proportion of the Reduced Form of Albumin During Cell-Free and Concentrated Ascites Reinfusion Therapy in Patients with Malignant Ascites.
Ohashi A; Nakai S; Yamada S; Kato M; Hasegawa M
Ther Apher Dial; 2019 Jun; 23(3):242-247. PubMed ID: 31033167
[TBL] [Abstract][Full Text] [Related]
11. CART: Cell-free and Concentrated Ascites Reinfusion Therapy against malignancy-related ascites.
Ito T; Hanafusa N
Transfus Apher Sci; 2017 Oct; 56(5):703-707. PubMed ID: 28916401
[TBL] [Abstract][Full Text] [Related]
12. Reappraisal of a Renovated Cell-free and Concentrated Ascites Reinfusion Therapy for Malignant Ascites.
Kim Y; Ajiki T; Ueda Y; Yoshida Y; Takahashi T; Fukuyama H; Fukuyama T; Hori Y
Anticancer Res; 2024 Feb; 44(2):613-619. PubMed ID: 38307557
[TBL] [Abstract][Full Text] [Related]
13. Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan.
Iwasa M; Ishihara T; Kato M; Isoai A; Kobayashi R; Torii N; Soneda N; Takei Y
Intern Med; 2019 Nov; 58(21):3069-3075. PubMed ID: 31292400
[TBL] [Abstract][Full Text] [Related]
14. [Cell-Free Ascites Reinfusion Therapy(CART)Modified by Keisuke Matsusaki(KM-CART)at Our Hospital].
Iwaki R; Shindo K; Kawahara H; Nanba N; Kuramoto Y; Beppu T; Uesugi T; Tanaka Y; Uesugi Y
Gan To Kagaku Ryoho; 2018 Dec; 45(13):2165-2167. PubMed ID: 30692319
[TBL] [Abstract][Full Text] [Related]
15. Feasibility, efficacy, and safety of cell-free and concentrated ascites reinfusion therapy (KM-CART) for malignant ascites.
Matsusaki K; Orihashi K
Artif Organs; 2020 Oct; 44(10):1090-1097. PubMed ID: 32242939
[TBL] [Abstract][Full Text] [Related]
16. [A New Treatment Strategy-Novel Cell-Free and Concentrated Ascites Reinfusion System(KM-CART)for Massive Malignant Ascites].
Matsusaki K
Gan To Kagaku Ryoho; 2016 Dec; 43(13):2490-2497. PubMed ID: 28028255
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of cell-free and concentrated ascites reinfusion therapy in the therapeutic management of advanced ovarian cancer patients with massive ascites.
Kawata Y; Nagasaka K; Matsumoto Y; Oda K; Tanikawa M; Sone K; Mori-Uchino M; Tsuruga T; Arimoto T; Osuga Y; Fujii T
Int J Clin Oncol; 2019 Apr; 24(4):420-427. PubMed ID: 30474762
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of reinfusion of concentrated ascitic fluid for malignant ascites: a concept-proof study.
Hanada R; Yokomichi N; Kato C; Miki K; Oyama S; Morita T; Kawahara R
Support Care Cancer; 2018 May; 26(5):1489-1497. PubMed ID: 29168037
[TBL] [Abstract][Full Text] [Related]
19. Novel cell-free and concentrated ascites reinfusion therapy (KM-CART) for refractory ascites associated with cancerous peritonitis: its effect and future perspectives.
; Matsusaki K; Ohta K; Yoshizawa A; Gyoda Y
Int J Clin Oncol; 2011 Aug; 16(4):395-400. PubMed ID: 21347629
[TBL] [Abstract][Full Text] [Related]
20. Ascitic IL-10 Concentration Predicts Prognosis of Patients Undergoing Cell-Free and Concentrated Ascites Reinfusion Therapy.
Ito T; Hanafusa N; Iwase S; Noiri E; Nangaku M; Nakagawa K; Miyagawa K
Ther Apher Dial; 2020 Feb; 24(1):90-95. PubMed ID: 31157953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
